{"id":"fampyra","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Impaired renal function disorder","Seizure disorder"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":{"chemblId":"CHEMBL284348","moleculeType":"Small molecule","molecularWeight":"94.12"},"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Voltage-gated potassium channel, Potassium voltage-gated channel subfamily C member 1, Potassium voltage-gated channel subfamily C member 2"},"_scrapedAt":"2026-03-28T01:53:28.251Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Multiple sclerosis","diseaseId":"multiple-sclerosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07171203","phase":"PHASE1","title":"Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2026-06","conditions":"Gastrointestinal Stromal Tumors","enrollment":18},{"nctId":"NCT04148781","phase":"EARLY_PHASE1","title":"Fampridine-SR and Optic Neuritis Recovery","status":"UNKNOWN","sponsor":"Courtney Casserly","startDate":"2022-03-22","conditions":"Optic Neuritis","enrollment":20},{"nctId":"NCT02208050","phase":"PHASE4","title":"A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS","status":"COMPLETED","sponsor":"University College Dublin","startDate":"2014-02-21","conditions":"Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis","enrollment":64},{"nctId":"NCT02849782","phase":"PHASE4","title":"Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine.","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2014-02-04","conditions":"Multiple Sclerosis","enrollment":89},{"nctId":"NCT01480063","phase":"","title":"An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice","status":"COMPLETED","sponsor":"Biogen","startDate":"2012-04-16","conditions":"Multiple Sclerosis","enrollment":4734},{"nctId":"NCT02146534","phase":"PHASE4","title":"Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients","status":"COMPLETED","sponsor":"Clinique Neuro-Outaouais","startDate":"2013-12","conditions":"Multiple Sclerosis","enrollment":44},{"nctId":"NCT01656148","phase":"PHASE4","title":"FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra","status":"COMPLETED","sponsor":"University of Southern Denmark","startDate":"2012-06","conditions":"Multiple Sclerosis","enrollment":108},{"nctId":"NCT02143167","phase":"PHASE4","title":"Resistance Training and Amino Pyridine in Multiple Sclerosis","status":"COMPLETED","sponsor":"University of Southern Denmark","startDate":"2014-05","conditions":"Multiple Sclerosis","enrollment":40},{"nctId":"NCT02219932","phase":"PHASE3","title":"Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2014-09","conditions":"Multiple Sclerosis","enrollment":646},{"nctId":"NCT01917019","phase":"PHASE3","title":"A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2013-08","conditions":"Multiple Sclerosis, Remittent Progressive, Multiple Sclerosis, Primary Progressive, Relapsing-Remitting Multiple Sclerosis","enrollment":101},{"nctId":"NCT01480076","phase":"PHASE4","title":"Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2012-02","conditions":"Multiple Sclerosis","enrollment":901},{"nctId":"NCT01597297","phase":"PHASE2","title":"Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.","status":"COMPLETED","sponsor":"Biogen","startDate":"2012-08","conditions":"Multiple Sclerosis","enrollment":132},{"nctId":"NCT01532154","phase":"","title":"Fampridine Pregnancy Exposure Registry","status":"TERMINATED","sponsor":"Biogen","startDate":"2015-08","conditions":"Multiple Sclerosis, Pregnancy","enrollment":1},{"nctId":"NCT01547234","phase":"","title":"Observational Study for Assessment of the Effect of Fampyra on the Manual Function of Persons With Multiple Sclerosis","status":"COMPLETED","sponsor":"Carmel Medical Center","startDate":"2013-02","conditions":"Multiple Sclerosis","enrollment":47},{"nctId":"NCT01576354","phase":"PHASE2","title":"Characterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple Sclerosis","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2012-03","conditions":"Multiple Sclerosis","enrollment":70},{"nctId":"NCT01720849","phase":"","title":"Efficiency of 4-aminopyridin (Fampyra) on Gait, Vision, Cognition, Fatigue and Micturation in Patients With Multiple Sclerosis","status":"UNKNOWN","sponsor":"Vestre Viken Hospital Trust","startDate":"2012-12","conditions":"Multiple Sclerosis, EDSS 4-7","enrollment":50},{"nctId":"NCT01215084","phase":"PHASE1","title":"A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers","status":"COMPLETED","sponsor":"Biogen","startDate":"2010-10","conditions":"Healthy","enrollment":36},{"nctId":"NCT01235221","phase":"PHASE3","title":"Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.","status":"COMPLETED","sponsor":"Biogen","startDate":"2010-12","conditions":"Multiple Sclerosis","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_2","status":"active","brandName":"Fampyra","genericName":"Fampyra","companyName":"Vestre Viken Hospital Trust","companyId":"vestre-viken-hospital-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fampyra, also known as extended release fampridine, is a small molecule that blocks voltage-gated potassium channels. It is indicated for the symptomatic improvement of walking in adults with multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}